Breaks Categories: News

WednesdayFeb 01, 2017 11:19 am

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Acquisition Expands Presence in New York

Solid waste management company National Waste Management Holdings, Inc. (OTC: NWMH) this morning announced some of the immediate growth opportunities stemming from its December acquisition of Northeast Data Destruction and Recycling, LLC. Notably, the acquisition immediately strengthened National Waste’s market reach in upstate New York, which now extends south to the Kingston, New York, headquarters of Northeast Data Destruction and Recycling. In line with its vertically integrated business model, the company plans to implement its existing offerings, including roll-off services, at its new Kingston operation in an effort to promote sustainable market growth. Looking forward, National Waste intends to continue…

Continue Reading

TuesdayJan 31, 2017 11:38 am

NetworkNewsBreaks – IsoRay, Inc. (NYSE: ISR) Initiates Pilot Study for Cesium-131 Impact on Head and Neck Cancer

Leading medical technology company IsoRay (NYSE: ISR) recently launched a new study to analyze the impact and safety of Cesium-131 brachytherapy seeds on recurrent neck and head cancer. The pilot study will be conducted at the Cleveland, Ohio, Case Western Reserve University’s Case Comprehensive Cancer Center, and it will begin enrollment of 42 subjects in early 2017. It is estimated that there are approximately 61,760 cases of neck and head cancer currently diagnosed in the United States. In case of recurrence, which happens with 30-40% of the cases, radiation therapy might not always be possible given the presence of vital…

Continue Reading

TuesdayJan 31, 2017 10:50 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) to Acquire Stake in Convectium, Creator of Cannabis Industry’s First-of-its-Kind Oil Filling Machine

SinglePoint (OTC: SING), a full-service mobile technology and marketing provider, this morning announced its LOI to acquire an interest in Convectium, the creator of a unique oil filling machine capable of filling cartridges or disposable vape pens for wholesale distribution to dispensaries. Convectium’s 710Shark and 710Seal system can fill and package up 100+ cartridges or disposable vape pens in 30 seconds. “To say we are excited about this opportunity is an understatement. Convectium's 710Shark and 710Seal system is incredible, and its capabilities are unmatched. After looking at hundreds of cannabis companies, finding an acquisition opportunity like we have found in…

Continue Reading

MondayJan 30, 2017 3:22 pm

NetworkNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Shares Higher on Encouraging Top-line Data from Trial of Ocular Bandage Gel

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are up more than 15% mid-day following topline results from the first-in-human pilot trial of the company’s EyeGate Ocular Bandage Gel (EyeGate OBG) in corneal epithelial effects. The study enrolled 39 subjects undergoing bilateral photorefractive keratectomy surgery to assess the safety and performance of EyeGate OBG on its own or combined with a bandage contact lens (BCL) compared to the current standard of care, artificial tears and BCL. The study demonstrated safety and tolerability of EyeGate OBG, with encouraging potential efficacy. “Corneal epithelial defects represent a large, underserved market with no approved eye drops…

Continue Reading

FridayJan 27, 2017 1:46 pm

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Tackles Lactose Intolerance, Metabolic Syndrome with RP-G28

Ritter Pharmaceuticals (NASDAQ: RTTR) is a specialty pharmaceutical company developing therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. The company’s first novel microbiome modulator, RP-G28, is currently in a phase 2b/3 study in humans for the treatment of lactose intolerance. More than one billion people suffer from lactose intolerance globally, and the company believes RP-G28 has the potential to become the first FDA-approved drug for the treatment of the disease. In previous human studies, RP-G28 has demonstrated significant beneficial changes to the gut microbiome that have been associated with supporting metabolic health. Recently, the company announced a collaborative…

Continue Reading

ThursdayJan 26, 2017 1:31 pm

NetworkNewsBreaks – Apricus Biosciences, Inc. (NASDAQ: APRI) Continues to Advance Erectile Dysfunction Treatment on Global Scale

Apricus Biosciences (NASDAQ: APRI) is focused on advancing the development and commercialization of its innovative, life-improving treatment products in urology and rheumatology. The company’s pipeline includes Vitaros®, a locally applied topical cream for the treatment of erectile dysfunction, a condition affecting roughly 150 million men worldwide. Containing alprostadil in combination with the company’s novel excipient, Vitaros delivers a rapid onset with significant efficacy and an encouraging safety profile. In a study of more than 3,000 patients, Vitaros demonstrated positive, clinically meaningful responses in measures of erectile function. The FDA recently determined that Vitaros, under current regulations, is now considered a…

Continue Reading

WednesdayJan 25, 2017 1:40 pm

NetworkNewsBreaks – COPsync, Inc. (NASDAQ: COYN) Inks Purchase Agreement with Arecibo, Puerto Rico

COPsync (NASDAQ: COYN) is trading 6% higher following this morning’s news that it has signed a contract with the municipality of Arecibo, Puerto Rico, to provide the COPsync law enforcement communication Network™ and the COPsync911™ threat-alert system. These COPsync systems are expected to provide increased safety for the city's residents and the millions of tourists that visit Puerto Rico annually. The contract is anticipated to be the company’s largest to date once fully realized. "Arecibo is an important city in Puerto Rico. It is home to the island's milk industry and supports a thriving tourist industry. We are honored that…

Continue Reading

WednesdayJan 25, 2017 9:59 am

NetworkNewsBreaks – UGE International Ltd. (UGEIF) Sets Quarterly Revenue Record for Q42016

UGE International (OTCQB: UGEIF) reported its largest revenue-generating quarter, posting fourth-quarter revenues for 2016 at $3.5 million, a considerable leap from its previous quarterly record of $1.5 million in the second quarter of last year. The company attributes the increase to progress made on projects that include 17 microgrid sites in New York City – where the company is managing project development and engineering work ahead of construction slated for 2017 - and the SolarShare FiT3 portfolio in Ontario. In its quest to maintain a competitive position in the renewable energy market, UGE has accumulated more than 330MW of global…

Continue Reading

TuesdayJan 24, 2017 9:42 am

NetworkNewsBreaks – CAS Medical Systems, Inc. (NASDAQ: CASM) Demonstrates Impressive Sales Growth with FORE-SIGHT Cerebral Oximetry

CAS Medical Systems (NASDAQ: CASM) is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products such as its FORE-SIGHT® Cerebral Oximeters. This innovative technology provides a highly accurate, non-invasive measurement of tissue oxygenation in the brain, enabling medical providers to improve patient care. The company recently reported preliminary unaudited top-line results for the three and 12 months ended December 31, 2016. Among other impressive figures, FORE-SIGHT Cerebral Oximetry sales increased 17% to approximately $18.0 million for 2016. The company estimated net sales for 2016 at approximately $22.2 million, up 14% from $19.5 million for 2015. For…

Continue Reading

FridayJan 20, 2017 1:26 pm

NetworkNewsBreaks – Concert Pharmaceuticals’ (NASDAQ: CNCE) CTP-656 Obtains Orphan Drug Designation from FDA

Concert Pharmaceuticals (NASDAQ: CNCE) this morning reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for CTP-656, a next generation CFTR potentiator for the treatment of cystic fibrosis. The designation provides incentives such as tax credits related to clinical trial expenses, an exemption from the FDA user fee, FDA assistance in clinical trial design, and potential market exclusivity for seven years following approval. In December 2016, Concert initiated a phase 2 trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline data from the ongoing phase 2 trial is expected by…

Continue Reading